A clinical trial in France evaluating the drug anakinra in the treatment of Covid-19 is suspended due to unexplained excess mortality among patients treated according to preliminary results of the trial, indicates the drug agency ANSM.
“Encouraging” results for severe forms of Covid-19 disease
This drug, anakinra (trade name: Kineret), initially intended for rheumatic diseases, had given “encouraging” results for severe forms of Covid-19 disease by significantly reducing the risk of death and the need for ” be put on a ventilator in intensive care, according to a study by a French medical team from the Paris Saint-Joseph Hospital Group (GHPSJ), published in the specialized journal The Lancet Rheumatology.
A drug still effective for other pathologies
This safety information does not call into question the benefit / risk ratio of anakinra when it is used in the validated indications of its marketing authorization (AMM) such as for example for rheumatoid arthritis, underlines the ANSM. . “Patients treated for one of these pathologies can therefore continue their treatment”. “If symptoms suggestive of Covid-19 appear”, the health agency invites them to consult their doctor.
Early excess mortality
The ANACONDA-COVID-19 trial conducted by the Tours University Hospital involves around thirty patients. The interim review of data showed early excess mortality in the group of patients treated with anakinra compared to the group that did not receive this drug. “A deleterious effect of anakinra cannot be excluded insofar as the information available at this stage does not make it possible to explain this difference” between these two groups of patients, notes the ANSM.
Anakinra targets, to block it, one of the cytokines, interleukin-1 (IL-1) involved in the “inflammatory storm” which results in acute respiratory distress syndrome (ARDS) requiring the assistance of a physician. artificial ventilation with the use of respirator. The other clinical trials with anakinra authorized in France in the Covid-19 indication are also suspended. These clinical trials were however already stopped or had not yet started, specifies the health agency.
Finally, the ANSM “reminds health professionals that at present, no study shows the interest of its use in the care of Covid patients”.
Source link by https://www.europe1.fr/societe/covid-19-suspension-en-france-dun-essai-avec-le-medicament-anakinra-4002046
*The article has been translated based on the content of Source link by https://www.europe1.fr/societe/covid-19-suspension-en-france-dun-essai-avec-le-medicament-anakinra-4002046
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!
These were the details of the news suspension in France of a trial with the drug anakinra for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at en24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
